AI-Driven Study Suggests GLP-1 Drugs Could Prevent 34,000 Heart Attacks and Strokes Annually
New AI-powered research suggests that GLP-1 drugs, commonly used for diabetes and obesity, could prevent up to 34,000 heart attacks and strokes annually by offering cardiovascular benefits to millions of Americans.
Canada Gains Access to Wegovy®, a New Treatment Option for Obesity
Discover the latest breakthrough in obesity treatment as Novo Nordisk launches Wegovy® in Canada on May 6, 2024. Learn how this once-weekly injection can transform obesity management and support millions of Canadians. Explore the effectiveness, safety data, and patient eligibility for Wegovy®.